Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1999 2
2001 1
2002 8
2003 28
2004 21
2005 66
2006 74
2007 80
2008 104
2009 130
2010 155
2011 197
2012 216
2013 244
2014 296
2015 248
2016 246
2017 247
2018 213
2019 200
2020 249
2021 263
2022 216
2023 184
2024 94

Text availability

Article attribute

Article type

Publication date

Search Results

3,330 results

Results by year

Filters applied: . Clear all
Page 1
Use of natalizumab in persons with multiple sclerosis: 2022 update.
Morrow SA, Clift F, Devonshire V, Lapointe E, Schneider R, Stefanelli M, Vosoughi R. Morrow SA, et al. Mult Scler Relat Disord. 2022 Sep;65:103995. doi: 10.1016/j.msard.2022.103995. Epub 2022 Jun 26. Mult Scler Relat Disord. 2022. PMID: 35810718 Free article. Review.
BACKGROUND: Natalizumab is a humanized monoclonal antibody used for treatment of highly active relapsing-remitting multiple sclerosis (MS). With more than 15 years of post-marketing experience with natalizumab in Canada, several real-world studies have shown the lon …
BACKGROUND: Natalizumab is a humanized monoclonal antibody used for treatment of highly active relapsing-remitting multiple sclerosis …
PB006: A Natalizumab Biosimilar.
Shirley M. Shirley M. Clin Drug Investig. 2024 May;44(5):367-370. doi: 10.1007/s40261-024-01360-4. Epub 2024 Apr 29. Clin Drug Investig. 2024. PMID: 38683493 Review.
The tolerability, safety and immunogenicity profiles of PB006 were similar to those of reference natalizumab, and switching from reference natalizumab to PB006 appeared to have no impact on tolerability or immunogenicity. The role of reference natalizumab in …
The tolerability, safety and immunogenicity profiles of PB006 were similar to those of reference natalizumab, and switching from refe …
Natalizumab: Perspectives from the Bench to Bedside.
Shirani A, Stüve O. Shirani A, et al. Cold Spring Harb Perspect Med. 2018 Dec 3;8(12):a029066. doi: 10.1101/cshperspect.a029066. Cold Spring Harb Perspect Med. 2018. PMID: 29500304 Free PMC article. Review.
Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to bedside perspective and the postmarketing experience standpoint. Natalizumab is a monoclonal antibody that inhibits the trafficking o …
Probably no other disease-modifying drug for multiple sclerosis has a more fascinating story than natalizumab from both the bench to …
Natalizumab in Multiple Sclerosis: Long-Term Management.
Clerico M, Artusi CA, Liberto AD, Rolla S, Bardina V, Barbero P, Mercanti SF, Durelli L. Clerico M, et al. Int J Mol Sci. 2017 Apr 29;18(5):940. doi: 10.3390/ijms18050940. Int J Mol Sci. 2017. PMID: 28468254 Free PMC article. Review.
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. ...In this review, we analyzed the results of clinical trials and case reports in relation to the following situations: natalizumab cont …
Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. ... …
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.
Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW; AFFIRM Investigators. Polman CH, et al. N Engl J Med. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. N Engl J Med. 2006. PMID: 16510744 Free article. Clinical Trial.
BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report the results of a two-year phase 3 trial of natalizumab in patients with relapsing multiple sclerosis. METHODS: Of a total of 942 patie …
BACKGROUND: Natalizumab is the first alpha4 integrin antagonist in a new class of selective adhesion-molecule inhibitors. We report t …
Natalizumab update.
Sweet BV. Sweet BV. Am J Health Syst Pharm. 2007 Apr 1;64(7):705-16. doi: 10.2146/ajhp060588. Am J Health Syst Pharm. 2007. PMID: 17384355 Review.
Data evaluating the efficacy and safety of natalizumab for the treatment of MS are available from published Phase II and III trials. ...Natalizumab is available only through a risk-minimization program run by the manufacturer. ...
Data evaluating the efficacy and safety of natalizumab for the treatment of MS are available from published Phase II and III trials. …
Natalizumab-Associated Primary Central Nervous System Lymphoma.
Nixon M, Menger RP, Kalakoti P, Thakur JD, Dossani RH, Sharma K, Nanda A, Guthikonda B. Nixon M, et al. World Neurosurg. 2018 Jan;109:152-159. doi: 10.1016/j.wneu.2017.09.131. Epub 2017 Sep 28. World Neurosurg. 2018. PMID: 28962961 Review.
In our report, we provide a comprehensive review of the literature on lymphoma development after natalizumab use, and we report an additional case of PCNSL development in a young woman who received natalizumab for her Crohn disease. ...CONCLUSIONS: Evidence document …
In our report, we provide a comprehensive review of the literature on lymphoma development after natalizumab use, and we report an ad …
Natalizumab treatment of multiple sclerosis: new insights.
Delbue S, Comar M, Ferrante P. Delbue S, et al. Immunotherapy. 2017 Jan;9(2):157-171. doi: 10.2217/imt-2016-0113. Epub 2016 Dec 22. Immunotherapy. 2017. PMID: 28004598 Review.
Natalizumab is a monoclonal antibody directed against the alpha4 chain of the very late activating antigen 4 and alpha4beta7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. ...The main focus of …
Natalizumab is a monoclonal antibody directed against the alpha4 chain of the very late activating antigen 4 and alpha4beta7 integrin …
Natalizumab for GVHD: too little or too late?
Quann K, Sacirbegovic F, Shlomchik WD. Quann K, et al. Blood Adv. 2023 Sep 12;7(17):5187-5188. doi: 10.1182/bloodadvances.2023010486. Blood Adv. 2023. PMID: 37698891 Free PMC article. No abstract available.
Natalizumab in relapsing-remitting multiple sclerosis.
Outteryck O. Outteryck O. Expert Rev Neurother. 2016 May;16(5):471-81. doi: 10.1586/14737175.2016.1169924. Epub 2016 Apr 8. Expert Rev Neurother. 2016. PMID: 27008031 Review.
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). ...Use of natalizumab in other inflammatory diseases of the nervous system has been less encouraging than in MS. ...
Natalizumab is the first humanized moclonal antibody indicated in the treatment of relapsing-remitting multiple sclerosis (RRMS). ... …
3,330 results